{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:51:23Z","timestamp":1791579083290,"version":"4.3.4"},"reference-count":103,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000964","name":"Arthritis National Research Foundation","doi-asserted-by":"publisher","award":["ANRF\/PAIR\/2025\/000029\/PAIR"],"award-info":[{"award-number":["ANRF\/PAIR\/2025\/000029\/PAIR"]}],"id":[{"id":"10.13039\/100000964","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["SR\/FST\/LS-1\/2019\/598"],"award-info":[{"award-number":["SR\/FST\/LS-1\/2019\/598"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["SR\/PURSE\/2023\/220(C)"],"award-info":[{"award-number":["SR\/PURSE\/2023\/220(C)"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.drudis.2026.104814","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:14:04Z","timestamp":1790147644000},"page":"104814","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug discovery strategies targeting B7-H3 (CD276) in lung and gastric cancers: From biological validation to next-generation small molecules, biologics and cell-based immunotherapies"],"prefix":"10.1016","volume":"31","author":[{"given":"Soorya","family":"Suresh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surabhi","family":"Maurya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhechchha","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9990-3283","authenticated-orcid":false,"given":"Aastha","family":"Dagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5307-866X","authenticated-orcid":false,"given":"Vivek","family":"Uttam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5993-1270","authenticated-orcid":false,"given":"Sandeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farman","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5539-3225","authenticated-orcid":false,"given":"Aklank","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104814_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-031-97242-3_1","article-title":"Cancer immunotherapy\u2014an overview","volume":"129","author":"Kulkarni","year":"2025","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.drudis.2026.104814_b0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.drudis.2026.104814_b0015","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.3390\/ijms25126471","article-title":"Immunotherapy based on immune checkpoint molecules and immune checkpoint inhibitors in gastric cancer\u2014narrative review","volume":"25","author":"Poniewierska-Baran","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104814_b0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-022-01325-0","article-title":"Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts","volume":"15","author":"Wang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2026.104814_b0025","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41420-024-02182-1","article-title":"The miRNA and PD-1\/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer","volume":"10","author":"Yadav","year":"2024","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.drudis.2026.104814_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117585","article-title":"Synthetic studies on the extracellular domain of the T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) using Trt-K10 solubilizing tags","volume":"99","author":"Iwamoto","year":"2024","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2026.104814_b0035","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2026.104814_b0040","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.7150\/ijbs.41105","article-title":"B7-H3, a checkpoint molecule, as a target for cancer immunotherapy","volume":"16","author":"Yang","year":"2020","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.drudis.2026.104814_b0045","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.immuni.2016.04.017","article-title":"Co-stimulatory and co-inhibitory pathways in autoimmunity","volume":"44","author":"Zhang","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.drudis.2026.104814_b0050","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.tcb.2019.07.002","article-title":"Regulatory mechanisms of inhibitory immune checkpoint receptors expression","volume":"29","author":"Curdy","year":"2019","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.drudis.2026.104814_b0055","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.drudis.2026.104814_b0060","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2026.104814_b0065","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.trecan.2025.02.007","article-title":"Targeting novel immune checkpoints in the B7-H family: advancing cancer immunotherapy from bench to bedside","volume":"11","author":"Luo","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.drudis.2026.104814_b0070","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","article-title":"B7-H3: an attractive target for antibody-based immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104814_b0075","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.3390\/ijms25073976","article-title":"B7-H3 expression in breast cancer and brain metastasis","volume":"25","author":"Joshi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104814_b0080","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2020.03.033","article-title":"Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer","volume":"133","author":"Yim","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.drudis.2026.104814_b0085","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1349-7006.2011.01877.x","article-title":"B7\u2013H3 expression in gastric cancer: a novel molecular blood marker for detecting circulating tumor cells","volume":"102","author":"Arigami","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1016\/j.drudis.2026.104814_b0090","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/modpathol.2010.95","article-title":"Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas","volume":"23","author":"Zang","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.drudis.2026.104814_b0095","doi-asserted-by":"crossref","first-page":"19458","DOI":"10.1073\/pnas.0709802104","article-title":"B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome","volume":"104","author":"Zang","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104814_b0100","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.4049\/jimmunol.172.4.2352","article-title":"Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains","volume":"172","author":"Steinberger","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2026.104814_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1495283","article-title":"B7-H3 in glioblastoma and beyond: significance and therapeutic strategies","volume":"15","author":"Babic","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104814_b0110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12935-015-0195-z","article-title":"B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2\/STAT3\/Slug signaling pathway","volume":"15","author":"Kang","year":"2015","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.drudis.2026.104814_b0115","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/gb-2005-6-6-223","article-title":"The B7 family of immune-regulatory ligands","volume":"6","author":"Collins","year":"2005","journal-title":"Genome Biol"},{"key":"10.1016\/j.drudis.2026.104814_b0120","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1084\/jem.20090681","article-title":"The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans","volume":"206","author":"Brandt","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2026.104814_b0125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/imr.12521","article-title":"The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3","volume":"276","author":"Janakiram","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.drudis.2026.104814_b0130","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.it.2013.07.003","article-title":"B7 family checkpoint regulators in immune regulation and disease","volume":"34","author":"Ceeraz","year":"2013","journal-title":"Trends Immunol"},{"key":"10.1016\/j.drudis.2026.104814_b0135","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.4049\/jimmunol.1700326","article-title":"ILDR2-Fc is a novel regulator of immune homeostasis and inducer of antigen-specific immune tolerance","volume":"200","author":"Podojil","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2026.104814_b0140","doi-asserted-by":"crossref","first-page":"10495","DOI":"10.1073\/pnas.0802423105","article-title":"Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses","volume":"105","author":"Hashiguchi","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104814_b0145","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1074\/mcp.TIR119.001433","article-title":"A platform for extracellular interactome discovery identifies novel functional binding partners for the immune receptors B7-H3\/CD276 and PVR\/CD155","volume":"18","author":"Husain","year":"2019","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.drudis.2026.104814_b0150","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-022-01364-7","article-title":"Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2026.104814_b0155","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/s41467-021-22618-x","article-title":"FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer","volume":"12","author":"Huang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104814_b0160","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1038\/s41467-025-58740-3","article-title":"Targeting site-specific N-glycosylated B7H3 induces potent antitumor immunity","volume":"16","author":"Huang","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104814_b0165","first-page":"4438","article-title":"B7-H3 increases the radioresistance of gastric cancer cells through regulating baseline levels of cell autophagy","volume":"11","author":"Li","year":"2019","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.drudis.2026.104814_b0170","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.yexcr.2012.09.006","article-title":"Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response","volume":"319","author":"Chen","year":"2013","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.drudis.2026.104814_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101874","article-title":"High expression of B7-H3 on monocyte\/macrophages in tumor microenvironment promotes lung cancer progression by inhibiting apoptosis","volume":"41","author":"Zhang","year":"2024","journal-title":"Transl Oncol"},{"key":"10.1016\/j.drudis.2026.104814_b0180","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.3389\/fonc.2019.01466","article-title":"Overexpression of B7-H3 in alpha-SMA-positive fibroblasts is associated with cancer progression and survival in gastric adenocarcinomas","volume":"9","author":"Zhan","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2026.104814_b0185","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10555-006-9001-7","article-title":"Role of tumor-associated macrophages in tumor progression and invasion","volume":"25","author":"Mantovani","year":"2006","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.drudis.2026.104814_b0190","doi-asserted-by":"crossref","first-page":"833","DOI":"10.21037\/tcr-23-1537","article-title":"B7-H3 promotes proliferation and migration of lung cancer cells by modulating PI3K\/AKT pathway via ENO1 activity","volume":"13","author":"Wu","year":"2024","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.drudis.2026.104814_b0195","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40425-019-0540-1","article-title":"Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung cancer (SCLC)","volume":"7","author":"Carvajal-Hausdorf","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.drudis.2026.104814_b0200","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/CAD.0000000000001577","article-title":"Diagnostic and prognostic value of serum soluble B7-H3 in nonsmall cell lung cancer","volume":"35","author":"Li","year":"2024","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.drudis.2026.104814_b0205","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lungcan.2016.11.013","article-title":"Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis","volume":"103","author":"Inamura","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.drudis.2026.104814_b0210","doi-asserted-by":"crossref","first-page":"71725","DOI":"10.18632\/oncotarget.17847","article-title":"B7-H3 promotes gastric cancer cell migration and invasion","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2026.104814_b0215","article-title":"Association of increased B7 protein expression by infiltrating immune cells with progression of gastric carcinogenesis","volume":"98","author":"Guo","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.drudis.2026.104814_b0220","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3748\/wjg.v12.i3.457","article-title":"Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis","volume":"12","author":"Wu","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.drudis.2026.104814_b0225","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/CBM-210178","article-title":"Evaluation of the role of soluble B7-H3 in association with membrane B7-H3 expression in gastric adenocarcinoma","volume":"33","author":"Huang","year":"2022","journal-title":"Cancer Biomark"},{"key":"10.1016\/j.drudis.2026.104814_b0230","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.3390\/ijms22042129","article-title":"Gastric carcinomas with stromal B7-H3 expression have lower intratumoural CD8+ T cell density","volume":"22","author":"Ulase","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104814_b0235","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3892\/mmr.2022.12595","article-title":"B7\u2011H3 promotes the epithelial\u2011mesenchymal transition of NSCLC by targeting SIRT1 through the PI3K\/AKT pathway","volume":"25","author":"Liao","year":"2022","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.drudis.2026.104814_b0240","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.2147\/OTT.S169811","article-title":"B7-H3 promotes metastasis, proliferation, and epithelial-mesenchymal transition in lung adenocarcinoma","volume":"11","author":"Yu","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.drudis.2026.104814_b0245","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.2147\/OTT.S237841","article-title":"B7-H3 regulates glioma growth and cell invasion through a JAK2\/STAT3\/slug-dependent signaling pathway","volume":"13","author":"Zhong","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.drudis.2026.104814_b0250","doi-asserted-by":"crossref","first-page":"10205","DOI":"10.2147\/CMAR.S222224","article-title":"B7-H3 induces ovarian cancer drugs resistance through an PI3K\/AKT\/BCL-2 signaling pathway","volume":"11","author":"Zhou","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.drudis.2026.104814_b0255","doi-asserted-by":"crossref","first-page":"5770","DOI":"10.7150\/jca.29838","article-title":"The immunoregulatory protein B7-H3 promotes aerobic glycolysis in oral squamous carcinoma via PI3K\/Akt\/mTOR pathway","volume":"10","author":"Li","year":"2019","journal-title":"J Cancer"},{"key":"10.1016\/j.drudis.2026.104814_b0260","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s41375-018-0331-6","article-title":"B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src\/STAT3 and c-Cbl-mediated degradation of SOCS3","volume":"33","author":"Lin","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2026.104814_b0265","first-page":"3189","article-title":"Enolase 1 differentially contributes to cell transformation in lung cancer but not in esophageal cancer","volume":"19","author":"Chen","year":"2020","journal-title":"Oncol Lett"},{"key":"10.1016\/j.drudis.2026.104814_b0270","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/bjc.2014.113","article-title":"Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c","volume":"110","author":"Nygren","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drudis.2026.104814_b0275","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41420-021-00527-8","article-title":"MicroRNA-326 attenuates immune escape and prevents metastasis in lung adenocarcinoma by targeting PD-L1 and B7-H3","volume":"7","author":"Shao","year":"2021","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.drudis.2026.104814_b0280","doi-asserted-by":"crossref","DOI":"10.1002\/jcb.30521","article-title":"Gastric cancer mesenchymal stem cells promote tumor glycolysis and chemoresistance by regulating B7H3 in gastric cancer cells","volume":"125","author":"Gao","year":"2024","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.drudis.2026.104814_b0285","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1097\/CM9.0000000000002772","article-title":"B7-H3 confers stemness characteristics to gastric cancer cells by promoting glutathione metabolism through AKT\/pAKT\/Nrf2 pathway","volume":"136","author":"Xia","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.drudis.2026.104814_b0290","doi-asserted-by":"crossref","first-page":"7518","DOI":"10.7150\/jca.59263","article-title":"B7-H3 inhibits apoptosis of gastric cancer cell by interacting with Fibronectin","volume":"12","author":"Sun","year":"2021","journal-title":"J Cancer"},{"key":"10.1016\/j.drudis.2026.104814_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108753","article-title":"Expression, regulation and clinical significance of B7-H3 on neutrophils in human gastric cancer","volume":"227","author":"Li","year":"2021","journal-title":"Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104814_b0300","first-page":"6606","article-title":"Expression of SNCG, MAP2, SDF-1 and CXCR4 in gastric adenocarcinoma and their clinical significance","volume":"7","author":"Zheng","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.drudis.2026.104814_b0305","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41419-021-03736-2","article-title":"B7-H3 suppresses doxorubicin-induced senescence-like growth arrest in colorectal cancer through the AKT\/TM4SF1\/SIRT1 pathway","volume":"12","author":"Wang","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2026.104814_b0310","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.3390\/cells11152401","article-title":"NRF2 and mitochondrial function in cancer and cancer stem cells","volume":"11","author":"Panieri","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2026.104814_b0315","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13244-021-01017-2","article-title":"Imaging side effects and complications of chemotherapy and radiation therapy: a pictorial review from head to toe","volume":"12","author":"Albano","year":"2021","journal-title":"Insights Imaging"},{"key":"10.1016\/j.drudis.2026.104814_b0320","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.drudis.2026.104814_b0325","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13045-022-01383-4","article-title":"Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies","volume":"15","author":"Kramer","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2026.104814_b0330","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004424","article-title":"Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I\/II trial","volume":"10","author":"Aggarwal","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.drudis.2026.104814_b0335","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-020-01024-8","article-title":"Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2026.104814_b0340","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13045-025-01729-8","article-title":"Targeting CD276 with Adapter-CAR T-cells provides a novel therapeutic strategy in small cell lung cancer and prevents CD276-dependent fratricide","volume":"18","author":"Kristmann","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2026.104814_b0345","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.7150\/thno.43991","article-title":"Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.drudis.2026.104814_b0350","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.drudis.2026.104814_b0355","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3389\/fphar.2020.01089","article-title":"Targeting B7-H3 immune checkpoint with chimeric antigen receptor-engineered natural killer cells exhibits potent cytotoxicity against non-small cell lung cancer","volume":"11","author":"Yang","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104814_b0360","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12935-022-02471-8","article-title":"Antitumor responses in gastric cancer by targeting B7H3 via chimeric antigen receptor T cells","volume":"22","author":"Sun","year":"2022","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.drudis.2026.104814_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101138","article-title":"Targeting CD276 by CAR-T cells induces regression of esophagus squamous cell carcinoma in xenograft mouse models","volume":"14","author":"Xuan","year":"2021","journal-title":"Transl Oncol"},{"key":"10.1016\/j.drudis.2026.104814_b0370","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/annonc\/mdw424","article-title":"Antibody drug conjugates: lessons from 20 years of clinical experience","volume":"27","author":"Tolcher","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2026.104814_b0375","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.3390\/cells12192393","article-title":"A CD276-targeted antibody-drug conjugate to treat non-small lung cancer (NSCLC)","volume":"12","author":"Zhang","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2026.104814_b0380","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12935-023-02991-x","article-title":"ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors","volume":"23","author":"Shin","year":"2023","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.drudis.2026.104814_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108988","article-title":"Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer","volume":"110","author":"Shao","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.drudis.2026.104814_b0390","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccell.2026.02.006","article-title":"HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: results from the ARTEMIS-001 phase 1a\/b trial","volume":"44","author":"Duan","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2026.104814_b0395","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1200\/JCO-25-02142","article-title":"Ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer: primary analysis of the Phase II IDeate-Lung01 Trial","volume":"44","author":"Rudin","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104814_b0400","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70544","article-title":"Vobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: final results of a phase 1 cohort expansion","volume":"132","author":"Shenderov","year":"2026","journal-title":"Cancer"},{"key":"10.1016\/j.drudis.2026.104814_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117141","article-title":"Small molecule inhibitors targeting PD-L1, CTLA4, Vista, TIM-3, and LAG3 for cancer immunotherapy (2020\u20132024)","volume":"283","author":"Cheng","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104814_b0410","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1831153","article-title":"Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export","volume":"9","author":"Chen","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.drudis.2026.104814_b0415","doi-asserted-by":"crossref","first-page":"30323","DOI":"10.18632\/oncotarget.8730","article-title":"Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)","volume":"7","author":"Zak","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2026.104814_b0420","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s42003-021-02191-1","article-title":"PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy","volume":"4","author":"Sasikumar","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.drudis.2026.104814_b0425","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1021\/acs.jmedchem.2c01801","article-title":"Novel small-molecule PD-L1 inhibitor induces PD-L1 internalization and optimizes the immune microenvironment","volume":"66","author":"Sun","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104814_b0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41401-020-0366-x","article-title":"Small molecule inhibitors targeting the PD-1\/PD-L1 signaling pathway","volume":"42","author":"Wu","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.drudis.2026.104814_b0435","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg6752","article-title":"Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models","volume":"15","author":"Ma","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2026.104814_b0440","doi-asserted-by":"crossref","first-page":"11464","DOI":"10.1021\/acs.jmedchem.3c00960","article-title":"Discovery of small-molecule TIM-3 inhibitors for acute myeloid leukemia using pharmacophore-based virtual screening","volume":"66","author":"Abdel-Rahman","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104814_b0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115583","article-title":"Identification of a novel small-molecule inhibitor targeting TIM-3 for cancer immunotherapy","volume":"212","author":"Wu","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drudis.2026.104814_b0450","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.str.2013.03.003","article-title":"Structure and T cell inhibition properties of B7 family member, B7-H3","volume":"21","author":"Vigdorovich","year":"2013","journal-title":"Structure"},{"key":"10.1016\/j.drudis.2026.104814_b0455","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.2147\/DDDT.S111443","article-title":"Druggability analysis and classification of protein tyrosine phosphatase active sites","volume":"10","author":"Ghattas","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.drudis.2026.104814_b0460","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1021\/ci800324m","article-title":"Identifying and characterizing binding sites and assessing druggability","volume":"49","author":"Halgren","year":"2009","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2026.104814_b0465","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1039\/C7MD00097A","article-title":"An insight into the therapeutic potential of quinazoline derivatives as anticancer agents","volume":"8","author":"Shagufta","year":"2017","journal-title":"Medchemcomm"},{"key":"10.1016\/j.drudis.2026.104814_b0470","first-page":"18170","article-title":"Purine scaffold in agents for cancer treatment","volume":"10","author":"Wimmer","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.drudis.2026.104814_b0475","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202202361","article-title":"Indole derived anticancer agents","volume":"7","author":"Mehra","year":"2022","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.drudis.2026.104814_b0480","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/jhet.4355","article-title":"Benzimidazole based derivatives as anticancer agents: structure activity relationship analysis for various targets","volume":"59","author":"Satija","year":"2021","journal-title":"J Heterocycl Chem"},{"key":"10.1016\/j.drudis.2026.104814_b0485","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1002\/cmdc.201800253","article-title":"Recent advances in the development of indazole-based anticancer agents","volume":"13","author":"Dong","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2026.104814_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105331","article-title":"Assessment of elementary derivatives of 1,5-benzodiazepine as anticancer agents with synergy potential","volume":"117","author":"Gawandi","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104814_b0495","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202502264","article-title":"Advances in quinoxaline derivatives: multi-target anticancer potential and nanocatalyst-driven synthesis","volume":"10","author":"Sharma","year":"2025","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.drudis.2026.104814_b0500","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202302778","article-title":"An updated overview on the synthesis and anticancer evaluation of quinazoline derivatives","volume":"8","author":"Kaur","year":"2023","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.drudis.2026.104814_b0505","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1039\/D0MD00422G","article-title":"\u03b2-Carboline-based molecular hybrids as anticancer agents: a brief sketch","volume":"12","author":"Soni","year":"2021","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.drudis.2026.104814_b0510","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/molecules28010193","article-title":"Acridine as an anti-tumour agent: a critical review","volume":"28","author":"Varakumar","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2026.104814_b0515","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202501173","article-title":"Exploring the anticancer properties of quinoxaline-based molecules: a systematic review","volume":"22","author":"Abdelall","year":"2025","journal-title":"Chem Biodivers"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:14:26Z","timestamp":1791576866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626002199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":103,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1359644626002199"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104814","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug discovery strategies targeting B7-H3 (CD276) in lung and gastric cancers: From biological validation to next-generation small molecules, biologics and cell-based immunotherapies","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104814","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104814"}}